53 related articles for article (PubMed ID: 34107622)
1. Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
[TBL] [Abstract][Full Text] [Related]
2. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis.
Zhao B; Zhao B; Chen F
Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):891-904. PubMed ID: 35913776
[TBL] [Abstract][Full Text] [Related]
5. The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2).
Starzyńska A; Sejda A; Adamski Ł; Adamska P; Pęksa R; Sakowicz-Burkiewicz M; Wychowański P; Jereczek-Fossa BA
Postepy Dermatol Alergol; 2022 Apr; 39(2):265-274. PubMed ID: 35645666
[TBL] [Abstract][Full Text] [Related]
6. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer.
Suehiro Y; Suenaga S; Kunimune Y; Yada S; Hamamoto K; Tsuyama T; Amano S; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Fujimoto Y; Kaino S; Shinjo K; Kondo Y; Sakaida I; Takami T; Nagano H; Yamasaki T
Oncology; 2022; 100(12):674-684. PubMed ID: 36244341
[TBL] [Abstract][Full Text] [Related]
7. High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.
Krueger K; Mayer Z; Gerckens M; Boeck S; Luppa P; Holdenrieder S
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289665
[TBL] [Abstract][Full Text] [Related]
8. Reliable Detection of Extracellular PD-L1 by DNA Computation-Mediated Microfluidics.
Zhang Y; Wu Q; Huang Y; Wang W; Lu Y; Kang S; Yang C; Song Y
Anal Chem; 2023 Jun; 95(24):9373-9379. PubMed ID: 37276048
[TBL] [Abstract][Full Text] [Related]
9. A Case of Pseudoelevation of Serum CA19-9 Level.
Li G; Lu T; Lv S
Clin Lab; 2024 Jan; 70(1):. PubMed ID: 38213206
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer.
Shi T; Zhou S; Zhang T; Han S; Zhang L; Fu F; Yan R; Zhang X
J Immunol Res; 2022; 2022():3013185. PubMed ID: 35966819
[TBL] [Abstract][Full Text] [Related]
11. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
[TBL] [Abstract][Full Text] [Related]
12. Identifying Effective Biomarkers for Accurate Pancreatic Cancer Prognosis Using Statistical Machine Learning.
Abu-Khudir R; Hafsa N; Badr BE
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835833
[TBL] [Abstract][Full Text] [Related]
13. Progress on diagnostic and prognostic markers of pancreatic cancer.
Yang H; Li W; Ren L; Yang Y; Zhang Y; Ge B; Li S; Zheng X; Liu J; Zhang S; DU G; Tang BO; Wang H; Wang J
Oncol Res; 2023; 31(2):83-99. PubMed ID: 37304241
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer.
Xue H; Qiu B; Wang H; Jiang P; Zhang W; Xue L; Wang J
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1193-1196. PubMed ID: 35983975
[No Abstract] [Full Text] [Related]
15. [Research progress in the regulation of tumor cell PD-L1 expression by N6-methyladenosine modification].
Xia CM; Zhu M; Zhu LF; Ji PZ; Wu PF; Yang YL; Liu B; Ma YC
Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):976-980. PubMed ID: 37670637
[TBL] [Abstract][Full Text] [Related]
16. A charming molecular profile in the wrong tissue: the pathologist in the era of molecular diagnostics in the gastrointestinal tract.
Parente P; Grillo F; Vanoli A; Mastracci L; Fassan M
Expert Rev Mol Diagn; 2023; 23(12):1045-1047. PubMed ID: 37997281
[No Abstract] [Full Text] [Related]
17. B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer.
Zhu Z; Teng KY; Zhou J; Xu Y; Zhang L; Zhao H; Zhang X; Tian L; Li Z; Lu T; Ma S; Li Z; Dai Z; Wang J; Chen X; Wu X; Pan Y; Shi W; You Z; Chen H; Chung V; Yu J; He S; Zhao X; Cao L; Li D
Front Oncol; 2022; 12():814312. PubMed ID: 35311080
[TBL] [Abstract][Full Text] [Related]
18. PD-L1, a Master Regulator of Immunity 2.0.
Kochan G
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901818
[TBL] [Abstract][Full Text] [Related]
19. Correction: Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
Qin X; Sun W; Wang C; Li M; Zhao X; Li C; Zhang H
Reprod Biol Endocrinol; 2023 Oct; 21(1):104. PubMed ID: 37907948
[No Abstract] [Full Text] [Related]
20. Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials.
Wu AQ; Benjamin DJ; Prasad V; Olivier T
Eur J Cancer; 2024 Apr; 201():113925. PubMed ID: 38364627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
